DecisionDx Test IDs High-Risk Among Low-Risk Melanoma Patients

The DecisionDx-Melanoma gene expression profile (GEP) test can identify high-risk patients who are likely to recur or die from melanoma within groups of patients often considered low risk based on traditional staging metrics, a recent study suggests.